JORGE E CORTES to Camptothecin
This is a "connection" page, showing publications JORGE E CORTES has written about Camptothecin.
Connection Strength
0.360
-
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer. 2006 Oct 01; 107(7):1525-9.
Score: 0.227
-
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer. 2004 Apr 01; 100(7):1449-58.
Score: 0.048
-
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res. 2002 Jul; 8(7):2134-41.
Score: 0.042
-
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia. Ann Oncol. 1999 May; 10(5):577-83.
Score: 0.034
-
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. Invest New Drugs. 2001; 19(1):13-20.
Score: 0.010